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ABSTRACT
It is 14 years since the IMGT/HLA database was
first released, providing the HLA community with
a searchable repository of highly curated HLA
sequences. The HLA complex is located within the
6p21.3 region of human chromosome 6 and contains
more than 220 genes of diverse function. Of these,
21 genes encode proteins of the immune system
that are highly polymorphic. The naming of these
HLA genes and alleles and their quality control is
the responsibility of the World Health Organization
Nomenclature Committee for Factors of the HLA
System. Through the work of the HLA Informatics
Group and in collaboration with the European
Bioinformatics Institute, we are able to provide
public access to these data through the website
http://www.ebi.ac.uk/imgt/hla/. Regular updates to
the website ensure that new and confirmatory se-
quences are dispersed to the HLA community and
the wider research and clinical communities. This
article describes the latest updates and additional
tools added to the IMGT/HLA project.
INTRODUCTION
The IMGT/HLA database was established to provide a
locus-speciﬁc database (LSDB) for the allelic sequences of
the genes in the HLA system, also known as the human
major histocompatibility complex (MHC). The MHC is
one of the most complex and polymorphic regions of the
human genome, with excess of 220 genes (1). The core
genes of interest in the HLA system are 21 highly poly-
morphic HLA genes, found within the 6p21.3 region of
the short arm of human chromosome 6, whose protein
products mediate human responses to infectious disease
and inﬂuence the outcome of cell and organ transplants.
Three distinct regions have been identiﬁed within the
MHC. The class I region is located at the telomeric end
of the MHC and encodes the genes for the HLA class
I molecules, HLA-A, -B and -C. These are co-dominantly
expressed on the cell surface and responsible for present-
ing intracellularly derived peptides to CD8-positive
T cells. The class II region lies at the centromeric end
of the MHC and encodes HLA class genes HLA-DRA,
-DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1
and -DPB1. HLA class II expression is limited to cells
involved in immune responses, where these molecules
present extracellularly derived peptides to CD4-positive
T cells. Located between the class I and class II regions
lies the class III region where a number of non-HLA genes
with immune function are located. With a nomenclature
covering more than 50 genes and 8000 alleles, there is an
obvious need for a curated LSDB to manage these highly
polymorphic variants. The ﬁrst public release of the
IMGT/HLA database was made on the 16 December
1998 (2). Since then the database has been updated
every 3 months, in a total of 55 releases, to include all
the publicly available sequences ofﬁcially named by the
World Health Organization (WHO) Nomenclature
Committee at the time of release.
The naming of new HLA genes and allele sequences and
their quality control is the responsibility of the WHO
Nomenclature Committee for Factors of the HLA
System, which ﬁrst met in 1968. This committee meets
regularly to discuss the issues of nomenclature and has
published 19 major reports (3–21) initially documenting
the serologically deﬁned HLA antigens and more
recently the genes and alleles deﬁned by nucleotide
sequences. The IMGT/HLA database provides the no-
menclature committee with the online tools necessary for
its task. The dissemination of new allele names and se-
quences is of paramount importance in the clinical trans-
plant setting, because the variation that distinguishes
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HLA alleles can have a critical impact on the outcome of a
haematopoietic stem cell transplant (22,23). The identiﬁ-
cation, veriﬁcation and publication of the sequences of
these variants through a centralized resource are necessary
for accurate identiﬁcation of HLA alleles in a clinical
setting. Sequencing of HLA alleles began in the late
1970’s, predominantly using protein-based techniques to
determine the sequences of HLA class I allotypes. The ﬁrst
complete HLA class I allotype sequence, B7.2, now known
as B*07:02:01, was published in 1979 (24). The ﬁrst HLA
class II allele, DRA*01:01, was deﬁned by protein
sequencing and later in 1982 by DNA sequencing
(25–27). The ﬁrst HLA DNA sequences or alleles were
named by the WHO Nomenclature Committee for
Factors of the HLA System (10) in 1987. At that time,
12 class I alleles and 9 class II alleles were named: in the
ﬁrst 8 months of 2012, the WHO Nomenclature
Committee was able to assign names to 1163 alleles
(Figure 1).
IMGT/HLA DATA SOURCES
The IMGT/HLA database receives submissions from
laboratories across the world. These submissions are
curated and analysed, and if they meet the strict require-
ments, an ofﬁcial allele designation is assigned.
The IMGT/HLA database is the ofﬁcial repository for
the WHO Nomenclature Committee for factors of the
HLA system and is the only way of receiving an ofﬁcial
allele designation for a sequence. The sequence is
then incorporated into the next 3-monthly release of the
database. Since its release in December 1998, the database
has received over 14 000 submissions. These submissions
come from a variety of sources; the majority are from
laboratories involved in clinical HLA typing, for hospitals
or donor registries, or commercial organizations perform-
ing contract HLA typing for large haematopoietic stem
cell donor registries. Further data have been submitted
following large-scale genome sequencing projects (1,28).
All submissions must meet strict acceptance criteria
before the sequence receives an ofﬁcial designation.
These minimum standards cover the methodologies used
to deﬁne the sequence, the length of sequence submitted
and the source of the sequence; the full list of the
minimum criteria can be seen at http://www.ebi.ac.uk/
imgt/hla/subs/submit.html. Around 3% of the submis-
sions received fail to meet these criteria and are rejected.
In addition, all the submissions received by the IMGT/
HLA database are also available from the International
Nucleotide Sequence Database Collaboration (INSDC)
(29). The INSDC consists of DNA DataBank of Japan
(Japan), GenBank (USA) and the EMBL-European
Nucleotide Archive (ENA) (UK) (30–32). The ENA
entries also contain database cross-references to the
IMGT/HLA entries. The cross-references to the IMGT/
HLA database are also included in ENSEMBL (33) and
vertebrate genome annotation (VEGA) entries (34).
Figure 1. The number of HLA alleles named each year and included in the IMGT/HLA Database. The recent surge in the number of submissions
received by the database is clearly shown.
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TOOLS AVAILABLE AT IMGT/HLA
The IMGT/HLA database provides a diversity of tools for
the analysis of HLA sequences. Some of these tools were
custom written for the IMGT/HLA database, and others
were incorporated from the existing set of tools provided
on the European Bioinformatics Institute’s (EBI) website
(35,36). The website (Figure 2) includes tools for producing
user-deﬁned sequence alignments at the protein, cDNA
and gDNA level. The user is also able to perform queries
for particular HLA alleles; the output provides access to
detailed information on any HLA allele, including
information on the ethnic origin of the source, database
cross-references and seminal publications. This informa-
tion is also available through integration with the
Sequence Retrieval System (SRS) service at EBI (37).
Tools have also been developed to support the labor-
atories that sequence HLA. The use of sequence-based
typing (SBT) as a method for deﬁning the HLA type
is well documented (38,39); most SBT typing stra-
tegies currently employed use the exon 2 and exon 3
sequences for HLA class I analysis and exon 2 alone
for HLA class II analysis. Because of the heterozygous
nature of the SBT analysis, the combinations of many
pairs of alleles may give an ambiguous typing result; cur-
rently, there are over 60 000 recognized ambiguous com-
binations. The IMGT/HLA maintains and regularly
updates a listing of these ambiguous allele combinations.
The document also includes a list of all alleles that are
identical over exons 2+3 for HLA class I and exon 2
for HLA class II.
Where possible, sequence data, both nucleotide and
protein, from the IMGT/HLA database is incorporated
into the EBI’s suite of search tools including FASTA
(40) and BLAST (41) and downloadable from the EBI’s
Figure 2. The IMGT/HLA homepage, which acts as a portal to the different tools provided on the website.
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File Transfer Protocol (FTP) directory in a variety of
commonly used formats like FASTA, MSF and PIR.
LATEST DEVELOPMENTS
In 2012, the IMGT/HLA database added an Extensible
Markup Language (XML) export to the data formats
available. XML is a simple but ﬂexible language that
deﬁnes a set of rules for encoding documents in a
format that is both human and machine readable.
Designed to meet the challenges of large-scale electronic
publishing, XML is playing an increasingly important role
in the exchange of scientiﬁc data. The data format has
been developed in a collaborative project between the
HLA Informatics Group of the Anthony Nolan
Research Institute and the Bioinformatics Department
of the National Marrow Donor Programme (NMDP).
The NMDP Bioinformatics group has previous success
in developing an XML format for electronically
communicating HLA typing data, the Histoimmu-
nogenetics Markup Language ﬁle format (42). This experi-
ence facilitated the collaboration to develop a similar
project for publishing the data contained within each
release of the IMGT/HLA database. The new format
combines the data present in the multiple ﬁles of each
quarterly IMGT/HLA release into a single ﬁle. The
IMGT/HLA database provides an FTP site for the
retrieval of sequences in a number of pre-formatted ﬁles.
The sequences are provided as FASTA, PIR and MSF
formats, as well as an archive of the sequence alignments
and an ENA ﬂat ﬁle like formatted copy of the database.
The NMDP Bioinformatics Department has also de-
veloped a suite of tools for importing data into different
database schema, both open source and proprietary,
allowing incorporation into different laboratory systems
(Figure 3). Additional XML exports are being developed
for other sections of the IMGT/HLA database. Further
developmental work on a suite of tools for integrating the
XML into laboratory systems used by HLA-typing
laboratories is underway.
HLA matching is a critical factor when considering
potential donors for patients receiving allogeneic trans-
plants for haematological disorders (22,23). The most
recent development on the IMGT/HLA website is an
online tool to implement the T-cell epitope matching al-
gorithm described by Zino et al. (43–45) and updated by
Fleischhauer and Shaw (46). This algorithm classiﬁes the
HLA-DPB1 alleles into a number of groups based on
functional studies and protein motifs. Predictive analysis
of the HLA-DPB1 mismatches between patient and donor
based on T-cell epitope (TCE) groups has the potential to
distinguish between mismatches that are tolerated (per-
missive) from those that increase the risks of poor
clinical outcome (non-permissive). This tool allows the
user to enter the HLA-DPB1 of a prospective patient
and donor pair and view the predicted TCEs and resulting
prediction of the effect of mismatching when selecting ap-
propriate donors for HSCT recipients. Any allele that
does not have a TCE group ‘protein’ is analysed for a
motif match to particular protein motifs of those alleles
with known TCE group. If the tool needs to predict the
TCE group for an allele, then a warning is issued within
the output to the user, to ensure that the lack of functional
studies is acknowledged. The implementation of an easy to
use online tool makes it simple for all those staff involved
with selecting donors for transplantation to factor in
DPB1 mismatches into their own search algorithms and
procedures.
Figure 3. The IMGT/HLA export combines a number of existing ﬁle formats and data source into a single format. The data are available from the
IMGT/HLA database. The tool set is available from the Bioinformatics Group, of the National Marrow Donor Program. Together these allow the
user to import the HLA data directly into their local database structure.
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A major challenge for the database is to keep up with the
increasing number of allele sequences that are being
submitted. In recent years, the number of sequences in
the database increased on average by 29% each year.
The database must develop new tools for the visualization
of sequences while maintaining the high standards set in
the presentation and quality of the HLA sequences and
nomenclature to the research community. The database
aims to continually develop new tools and reﬁne existing
tools to meet this challenge.
CONCLUSIONS
The IMGT/HLA database provides a centralized resource
for everybody interested, clinically or scientiﬁcally, in the
HLA system. The database and accompanying tools allow
the study of HLA alleles from a single site on the World
Wide Web. It aids in the management and development of
HLA nomenclature, providing a continuing and updated
resource for the WHO Nomenclature Committee. The
challenges for the database are to keep up with this
increase in submitted sequences, keep pace with the
increasing difﬁculties in performing analyses on the
larger datasets and develop new tools for the visualization
of the sequences while maintaining the high standards set
in the presentation and quality of the HLA sequences and
nomenclature to the research community.
LICENSING
The IMGT/HLA database is covered by the Creative
Commons Attribution-NoDerivs Licence, which is applic-
able to all copyrightable parts of the database, which
includes the sequence alignments. This means that users
are free to copy, distribute, display and make commercial
use of the databases in all legislations, provided they give
the appropriate credit (47,48). If users intend to distribute
a modiﬁed version of the data in any form, then they must
ask us for permission; this can be done by contacting
hla@alleles.org for further details of how modiﬁed data
can be reproduced.
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